Boc5: A New Drug for Diabetes and Weight Loss
Author Information
Author(s): Su Haoran, He Min, Li Hongmei, Liu Qing, Wang Jia, Wang Yiqian, Gao Weiwei, Zhou Ling, Liao Jiayu, Young Andrew A., Wang Ming-Wei
Primary Institution: The National Center for Drug Screening, Shanghai, China
Hypothesis
The study aimed to determine the in vivo pharmacologic properties of Boc5 in both normal and diabetic mice, focusing on glycemic control and weight loss.
Conclusion
Boc5 is the first non-peptidic molecule shown to activate a range of antidiabetic effects.
Supporting Evidence
- Boc5 treatment led to a significant reduction in HbA1c levels in diabetic mice.
- Weight loss in db/db mice was observed with Boc5 administration.
- Boc5 improved insulin sensitivity in diabetic mice.
- Boc5 reduced food intake by up to 50% in db/db mice.
- Boc5 slowed gastric emptying in both db/db and wildtype mice.
- Boc5 treatment resulted in a significant decrease in plasma leptin levels.
Takeaway
Boc5 is a new medicine that helps diabetic mice control their blood sugar and lose weight.
Methodology
C57BL/6J and db/db mice were treated daily with Boc5 for 4 weeks, assessing various pharmacologic parameters.
Limitations
The study primarily focused on mouse models, which may not fully represent human responses.
Participant Demographics
C57BL/6J and db/db mice, both sexes, aged eight weeks.
Statistical Information
P-Value
0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website